- Home
- ISD vs RIGL Comparison
ISD vs RIGL Comparison
Compare ISD & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISD
- RIGL
- Stock Information
- Founded
- ISD 2012
- RIGL 1996
- Country
- ISD United States
- RIGL United States
- Employees
- ISD N/A
- RIGL N/A
- Industry
- ISD Trusts Except Educational Religious and Charitable
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ISD Finance
- RIGL Health Care
- Exchange
- ISD Nasdaq
- RIGL Nasdaq
- Market Cap
- ISD 472.3M
- RIGL 537.6M
- IPO Year
- ISD N/A
- RIGL 2000
- Fundamental
- Price
- ISD $14.45
- RIGL $35.28
- Analyst Decision
- ISD
- RIGL Buy
- Analyst Count
- ISD 0
- RIGL 6
- Target Price
- ISD N/A
- RIGL $39.83
- AVG Volume (30 Days)
- ISD 127.1K
- RIGL 567.6K
- Earning Date
- ISD 01-01-0001
- RIGL 11-04-2025
- Dividend Yield
- ISD 9.69%
- RIGL N/A
- EPS Growth
- ISD N/A
- RIGL 2698.26
- EPS
- ISD N/A
- RIGL 6.20
- Revenue
- ISD N/A
- RIGL $282,076,000.00
- Revenue This Year
- ISD N/A
- RIGL $59.93
- Revenue Next Year
- ISD N/A
- RIGL N/A
- P/E Ratio
- ISD N/A
- RIGL $5.68
- Revenue Growth
- ISD N/A
- RIGL 79.13
- 52 Week Low
- ISD $10.98
- RIGL $14.63
- 52 Week High
- ISD $13.17
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- ISD 50.12
- RIGL 60.36
- Support Level
- ISD $14.40
- RIGL $28.08
- Resistance Level
- ISD $14.56
- RIGL $39.56
- Average True Range (ATR)
- ISD 0.13
- RIGL 1.97
- MACD
- ISD 0.00
- RIGL 0.89
- Stochastic Oscillator
- ISD 46.43
- RIGL 62.66
About ISD PGIM High Yield Bond Fund Inc.
PGIM High Yield Fund Inc is a diversified, closed-end management investment company, active in the financial services domain. The Fund's investment objective is to provide a high level of current income. It invests at least 80% of its investable assets in a diversified portfolio of high-yield fixed-income instruments that are rated below investment grade with varying maturities and other investments.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.